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Nipah virus (NiV) is a highly pathogenic paramyxovirus that causes pulmonary disease and encephalitis
in humans with 40–70% fatality. Interactions between NiV and the human immune system remain poorly
understood. Here, we demonstrate the effects of NiV infection on DC and T cell function. Using an in vitro
system, we found that NiV infects and replicates at low levels in DCs and induces the expression of TNF-α,
IL-1α, IL-1β, IL-8, and IP-10. NiV infection activates DCs, and upregulates the expression of CD40, CD80,
and CD86. Also have reduced levels of bcl2 and high levels of active caspase 3, suggesting the induction
of apoptosis. DCs infected by NiV are unable to efﬁciently prime CD4 and CD8 T cells, but instead induce
apoptosis in T cells. Interestingly, DCs treated with inactivated NiV also show signs of apoptosis. These
ﬁndings indicate that NiV infected DCs could play an important role in NiV pathogenesis.
Published by Elsevier Inc.Introduction
Nipah virus (NiV) is a highly pathogenic paramyxovirus belong-
ing to the Henipavirus genus, which it shares with Hendra virus
(Mayo, 2002). NiV and Hendra virus are 80–90% homologous at
the genetic and antigenic levels (Halpin and Mungall, 2007; Rota
and Lo, 2012). NiV was ﬁrst identiﬁed during the 1998–1999
outbreak in Malaysia and Singapore (Chua et al., 1999). In this
outbreak, 265 human cases were identiﬁed, with 105 fatalities and
over 1 million pigs were slaughtered (Bellini et al., 2005; Halpin
and Mungall, 2007; Parashar et al., 2000). Subsequent recurring
NiV outbreaks have been reported in Bangladesh and India since
2001 (Bellini et al., 2005; Lo et al., 2012; Luby et al., 2009b;
Rahman et al., 2012). The fatality rate of NiV found in Bangladesh
is ∼70%, compared to 40% in Malaysia (Halpin and Mungall, 2007).
NiV is transmitted from bats to pigs to humans (as in Malaysia) or
directly from bats to humans (as in Bangladesh), and is capable of
human-to-human transmission (Chua et al., 2002; Gurley et al.,
2007; Luby et al., 2009a) Due to its mode of transmission and high
fatality rates, NiV is considered as a high containment biosafety
level-4 (BSL-4) virus.
NiV causes severe infection in both humans and animals. Its
incubation period ranges from a few days to several weeks (Wong
and Tan, 2012). The virus probably enters through aerosol, initially
lung endothelial cells and alveolar macrophages. From the lungs, NiV
spreads to peripheral organs, like spleen, lungs, heart, and kidneys. NiV
infects a variety of cell types, including parenchymal cells, endothelialInc.
ta).cells, smooth muscle cells, nerve cells, and monocytes (Wong and Tan,
2012). Ephrin B2 and B3 have been identiﬁed as NiV receptors; while
ephrin B2 is the higher-afﬁnity receptor used by both Hendra and NiV,
ephrin B3 is a functional receptor only for NiV, despite a comparatively
lower afﬁnity for the NiV glycoprotein (Bonaparte et al., 2005; Negrete
et al., 2005, 2006).
NiV pathology in humans includes vasculitis, endothelial multi-
nucleated syncytia, and thrombosis. Initially, NiV causes non-
speciﬁc symptoms like fever, headache, and drowsiness, and
progresses to pulmonary disease or encephalitis, and death (Lam
and Chua, 2002). NiV pulmonary syndrome is an inﬂuenza-like
illness, with hypoxemia and diffuse alveolar shadowing on chest
X-rays. Neurological signs include confusion, motor deﬁcits, and
seizures (Lam and Chua, 2002; Wong and Tan, 2012).
Dendritic cells (DCs) play a central role in initiating host innate
and adaptive immune responses. Immature DCs capture viruses,
process antigens, and becomes mature and activated. Activated
DCs produce anti-viral cytokines and chemokines to limit viral
replication and spread. Mature DCs upregulate MHC Class II and
other co-stimulation molecules on the cell surface, and migrate to
draining lymph nodes to activate CD4 and CD8 T cells and initiate
humoral and cellular responses to combat infection (Pollara et al.,
2005). A number of paramyxoviruses, like measles (Grifﬁn, 2010),
respiratory syncytial (Guerrero-Plata et al., 2009), and simian/
parainﬂuenza (Pejawar et al., 2005) viruses, are known to replicate
in DCs. Among these, measles virus severely alters DC function,
causing T cell anergy and immunosuppression (Grifﬁn, 2010).
In this report, we document the modulation of DC function by
NiV infection. Using an in vitro system, we show that NiV
productively infects DCs and induces the production of certain
chemokines and cytokines. In addition both NiV infection of DCs
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co-stimulatory molecules and induce apoptosis; However, DCs
infected with NiV are unable to stimulate CD4 and CD8 T cells.
Results
NiV infection of DCs
Although a prior study had documented NiV infection of DCs,
endogenous levels of the functional NiV receptors ephrin B2 and B3
were not evaluated at the protein level (Mathieu et al., 2011).
We examined the expression of ephrin B2 and B3 in human
monocyte-derived DCs by ﬂow cytometry, and detected low levels of
ephrin B3 at the cell surface but not ephrin B2 (Fig. 1A). Our results are
contrary to a previous report of low ephrin B2 mRNA expression levels
and undetectable ephrin B3 mRNA in DCs (Mathieu et al., 2011). Vero-
E6 cells were used as positive controls. Both DCs and Vero-E6 cells
show low levels of ephrin B3 expression (Fig. 1A) and did not express
signiﬁcant levels of ephrin B2, whereas ∼13% of Vero-E6 cells have
high levels of ephrin B2 receptor (Fig. 1A).
We then infected immature DCs with puriﬁed NiV or treated
with puriﬁed inactivated NiV, and then stained the cells for NiV
antigen by IFA. Approximately 60–65% cells were positive for NiV
antigen in NiV infected cultures (Fig. 1B). A small percentage
(2–5%) of DCs was also weakly positive for NiV antigen in cells
treated with puriﬁed inactivated NiV. Next, we examined viral
replication by determining viral RNA levels in DCs (Fig. 1C). Viral
genome copy numbers increased two-fold by day 1, but remained
relatively constant at days 2 and 3, and gradually decreased at
later time points (data not shown). Together these ﬁndings suggest
that NiV infects DCs, but does not replicate efﬁciently in
these cells.
NiV induces cytokine and chemokine expression in DCs
We next determined whether NiV induces cytokine and
chemokine expression in DCs. DCs were infected with puriﬁed NiVFig. 1. Nipah virus (NiV) infection of dendritic cells (DCs). Monocyte-derived dendritic ce
E6 cells were used as positive controls. (A) Histograms showing receptor staining. Black
for NiV antigen on DCs 24 h post-infection (magniﬁcation 20 ). Viral antigen is staine
replication (determined as viral RNA copy numbers per ng of total RNA) in DCs 0–3 daor with inactivated NiV; cell culture supernatants were collected
from day 1 to 4 post-infection and tested for the presence of 26
cytokines and chemokines by a multiplex assay. Out of the 26
cytokines tested, only 7 showed signiﬁcant increases or decreases
compared to the mock-infected controls: IL-1β, TNF-α, MIP-1α, IL-10,
IP-10, IL-8, and IL-1α (Fig. 2). Expression of IL-1β, TNF-α, IL-10, and
MIP-1α peaked at day 1 and decreased by day 4 post-infection. Levels
of these cytokines are signiﬁcantly higher in DCs infected with live
virus than in those treated with inactivated virus. Inactivated NiV-
treated cells also express TNF-α, IP-10 and MIP-1α. We did not
observe any signiﬁcant differences in IL-8 levels between DCs
infected with NiV or treated with inactivated NiV. Also, we saw no
signiﬁcant induction of IFN-α and β in infected DCs (data not shown).NiV causes activation-induced cell death in DCs
We next examined the effects of NiV infection on DC function.
Monocyte-derived DCs marked as CD1aþ cells infected with
puriﬁed NiV or treated with puriﬁed inactivated NiV were stained
for the presence of activation and apoptotic markers. Fig. 3 shows
mean ﬂorescent intensity of various markers on days 5 and 8 post-
infection. We used these time points to observe apoptosis followed
by activation signals. Usually, pathogens cause activation and
induce death signals in cells that are detectable later after infec-
tion. The left panel of Fig. 3A shows histogram plots for activation
and co-stimulation molecules on CD1aþ cells on day 5 post-
infection. The data indicate that MHC Class II levels in CD1aþ
cells were upregulated in cells treated with inactivated NiV or with
inactivated Ebola virus, but not cells infected with NiV. We also
studied different co-stimulation molecules on the surface of
CD1aþ cells, and saw signiﬁcant upregulation of CD40, CD80,
and CD86 levels in infected cells and cells treated with inactivated
NiV, or inactivated Ebola virus. The MFI levels of CD40 on CD1aþ
cells increased from 96 to 147 in NiV infected, and 162 in those
receiving inactivated NiV. MFI of CD80 on CD1aþ cells changedlls were tested for NiV receptors ephrin B2 and ephrin B3 by ﬂow cytometry. Vero-
lines show isotype controls and red line represent receptor staining. (B) IFA staining
d with FITC and shown in green; the nucleus (blue) is stained with DAPI. (C) NiV
ys post-infection. Results are representative of 3 experiments.
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Fig. 2. Cytokines and chemokines from DCs infected with NiV. DCs were infected with either puriﬁed live or inactivated NiV (MOI¼5). Supernatants were collected on 1–4
days post-infection. Expression of 26 cytokines was tested by Luminex method. Only 7 cytokines show a signiﬁcant difference over uninfected controls. Y-axis shows
cytokine concentration in pg/mL; x-axis shows days post-infection. Data is plotted as mean 7SEM. Data are representative of 3 experiments.
Fig. 3. NiV causes activation-induced cell death in DCs. FACS analysis of DC activation and apoptosis on days 5 (A) and 8 (B) post-infection. Left panels in A and B show
histograms for MHC class II, CD40, CD80, and CD86 molecules on the x-axis, and cell numbers on the y-axis. Values inside the plots represent mean ﬂorescent intensity (MFI)
of each molecule. In (A) scatter plots on right-hand panel show bcl2 and active caspase 3 on the x-axis, and FSC on the y-axis. Histogram in lower panel indicates FSC on DCs
on day 5 post-infection. In (B) scatter plots show Fas, bcl2, and active caspase 3 levels on the x-axis, and FSC on the y-axis on day 8 post-infection. These results are
representative of 7 independent experiments. MFI of isotype controls for CD40, CD80, and CD86 were 30, and for bcl2 and caspase 3 were 20.
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in cells treated with inactivated virus. Similarly, MFI of CD86 on
CD1aþ cells increased from 414 in uninfected cells to 1854 and
1435 in infected cells and cells treated with inactivated NiV,
respectively. These increases suggest that inactivated NiV activates
DCs even in the absence of virus replication. These experiments
were repeated seven times. The MFI of MHC class II and co-
stimulatory molecules varied only between 5% and 8% in seven
independent experiments.
We also examined apoptosis markers (bcl2 and activated
caspase 3) on CD1aþ infected smaller cells (FSClow). Usually DCs
appear in the 400–800 channels, as shown in the lowest right
panel of Fig. 3A. Only 27% of CD1aþ cells were FSClow (o400
channels) in uninfected controls, compared to 58% and 42% of
infected cells or cells treated with inactivated NiV, respectively. Of
the CD1aþ cells in uninfected controls, 24% are also FSClow bcl2low,
and 13% are FSClow active caspase 3high. However, the number of
CD1aþFSClowbcl2low cells increased in NiV-infected cells. In NiV-
infected CD1aþ cells, 49% of the FSClow bcl2low, and 24% were
FSClow active caspase 3high. Similarly, CD1aþ cells treated with
inactivated virus, 37% are also FSClow bcl2low, and 16% are FSClow
active caspase 3high. Treatment with inactivated Ebola virus does
not change the FSClow population or apoptotic marker expression
compared to uninfected controls.
However, NiV-infected DCs show high CD40, 80, and 86 levels
compared to uninfected controls on day 8 post-infection, although
CD80 and CD86 levels are lower on day 8 than they were on day 5
(Fig. 3B). These data indicate that DCs are activated by NiV
infection.
We then examined Fas expression in FSClow cells. Approxi-
mately 40% and 32% CD1aþ NiV infected cells and inactivated
NiV-treated cells, respectively, are FashighFSClow, compared to
13% in controls (Fig. 3B) on day 8 post-infection. We did not
ﬁnd any signiﬁcant change in numbers of FashighFSClow on
CD1aþcells between uninfected and NiV infected groups on day
5 post infection (8% versus 9.1%, respectively). The number of
FSClowbcl2low cells in infected DCs increased from day 5; 72% and
51% of NiV infected cells and inactivated NiV-treated cells, respec-
tively, are FSClow bcl2low. Similarly, 51% of NiV-infected cells and
43% of inactivated NiV-treated cells are FSClowactive caspase 3high,
compared to 11% of uninfected controls (Fig. 3B). These data
suggest that NiV causes activation-induced cell death in DCs
independently of viral replication.NiV-infected DCs induces T cell apoptosis
We found that DCs infected with NiV show an activated
phenotype, so we next determined whether these activated DCs
can induce T cell priming. We co-cultured infected DCs with T cells,
and determined the expression of T cell activation markers such as
CD25, CD62Llow, and CD44high on CD4 and CD8 T cell populations
on day 8 post-infection. In addition we also determined induction
of apoptosis in T cells as we did with the DCs.
We found that DCs infected with NiV partially activate CD4 T
cells, as no upregulation of CD25 and CD44 molecules on these
cells was observed (Fig. 4A). However, CD4 T cells do down-
regulate CD62L: MFI of CD62L was 699 in uninfected controls and
394 in NiV infected cells. Surprisingly, a small percentage (6%) of
CD4þFSChigh cells have the active caspase 3high phenotype (com-
pare to 4% of controls), suggesting that CD4 T cells undergo a
partial and insufﬁcient activation. Interestingly, DCs treated with
inactivated NiV were able to induce CD4 T cells activation more
than DCs infected with virus: 28% CD3þ4þ cells are CD25þ v. 19%
controls; 47% are CD62Llow v. 18% controls; 11% CD44high v. 7%
controls, and 15% are FSChigh active caspase 3high v. 4% controls(Fig. 4A). DCs treated with inactivated Ebola virus were able to
activate CD4 T cells.
Approximately 12% of CD3þ8þ T cells were CD25þ v. 6%
controls, and 20% cells were CD62Llow v. 8% controls, again
suggesting that DCs infected with NiV partially activate CD8 T
cells (Fig. 4B). DCs treated with inactivated NiV were able to
activate CD8 T cells better than virus infection: 43% inactivated
NiV-infected cells were CD25þ v. 6% controls; 34% were CD62Llow
v. 8% controls; 11% FSChigh cells were active caspase 3high v. 4%
controls (Fig. 4B). DCs treated with inactivated Ebola virus were
able to activate CD8 T cells.
Surprisingly, we found that CD4 and CD8 T cells also expressed
low levels of bcl2: 58% and 40% of infected CD4 T cells or
inactivated NiV treated cells, respectively, were FSClowbcl2low,
compared to 7% of mock control cells and 9% in cells treated with
inactivated Ebola virus (Fig. 4C). Similarly, 54% and 20% infected
CD8 T cells or inactivated NiV treated cells were FSClowbcl2low (14%
uninfected controls and 11% in inactivated Ebola virus samples,
Fig. 4C). These data suggest that NiV-infected DCs do not induce
sufﬁcient priming of CD4 and CD8 T cells, but induce apoptotic
signals in these cells. To verify that the priming is DC-dependent,
we examined various activation and apoptotic markers in T cells
without DCs. We found no upregulation of CD25 or CD44, and no
change in bcl2 levels, suggesting that activation and apoptosis of T
cells is DC-dependent (data not shown). We also found that T cells
do not replicate Nipah virus. We test this with viral antigen by
protein assay and also by RNA levels and did not see any change in
the levels compared to controls.Discussion
Our study is the ﬁrst to show that Nipah virus alters DC
function and thus negatively affects host cell-mediated immunity.
Our results conﬁrm a previous report that NiV can infect DCs, but
cannot replicate to high titers (Mathieu et al., 2011). In human
endothelial cells, NiV can induce various chemokines and cyto-
kines, particularly IP-10 and IL-8 (Lo et al., 2010). IL-8 primarily
attracts neutrophils and has less effect on monocytes and T cells
(Mahalingam et al., 1999). IP-10 attracts activated T cells and
natural killer cells, and is associated with anti-viral activities
(Mahalingam et al., 1999). Previous reports have shown that both
infectious and non-infectious central nervous system pathology is
associated with high levels of these cytokines (Glabinski and
Ransohoff, 1999), suggesting that they may play an important role
in NiV pathogenesis and chemotaxis. Activated DCs can be a source
of these cytokines. In addition, NiV infection upregulates IL-10, an
anti-inﬂammatory immune-suppressor cytokine primarily pro-
duced by the monocytes and DCs. In general, IL-10 downregulates
Th1 response, inhibits CD8 T cell response (O'Garra et al., 2008),
and reduces IFN-γ, IL-2, and TNF-α, thus inhibiting the inﬂamma-
tory response (Brockman et al., 2009). In our study, IL-10 is
up-regulated early in the infection, and then decreases, in a course
similar to viral replication. It is possible that IL-10 is involved in
downregulating and/or modifying CD4 and CD8 T cell responses in
NiV infection. Pathways underlying the induction of these cyto-
kines and their role in the cellular response to NiV infection
remain to be determined.
A number of viruses, like human immunodeﬁciency (Rodriguez
-Plata et al., 2012), Ebola (Mahanty et al., 2003), herpes simples
(Salio et al., 1999), and measles viruses (Servet-Delprat et al.,
2000b), interfere with DC function and affect T cell responses. The
measles virus infects DCs and upregulate MHC-class II, CD40, 80,
and 86 molecules on DC surface (Schnorr et al., 1997; Servet-
Delprat et al., 2000b). DCs do not undergo apoptosis until T cells
are co-cultured with them, but adding T cells increases virus
Fig. 4. DCs infected with NiV are unable to prime CD3þCD4þ (A) and CD3þ8þ (B) T cells in vitro. FACS analysis of CD25, CD62L, and CD44 on day 8 post-infection. Naive T
cells were cultured with DCs infected with either live or inactivated NiV, or with inactivated Ebola virus 8 days, and activation and apoptosis markers were visualized.
Lowermost panel is a scatter plot of active caspase 3 in CD4 and CD8 T cells. Numbers inside the plots represent MFI and percentage of cells that are positive for that marker,
respectively. (C) Bcl2 levels on FSChigh or FSClow for CD3þ4þ and CD3þ8þ T cells. Data are representative of 3 experiments. MFI of isotype controls for CD25, CD62L, and
CD44 were 30, and were 20 for bcl2 and active caspase 3.
M. Gupta et al. / Virology 441 (2013) 49–56 53replication and DC death (Fugier-Vivier et al., 1997). DC death is
associated with expression of Fas/Fas ligands and TNF-α-related
apoptosis-inducing ligand (TRAIL) (Servet-Delprat et al., 2000a;
Vidalain et al., 2000). In our study, NiV, even when inacti-
vated, can upregulate co-stimulatory molecules. DCs activated by
NiV also express low levels of bcl2 and high levels of active
caspase 3 and Fas molecules, and undergo cell death. This DC
apoptosis does not require any other cells and is replication-
independent. Whether this cell death is Fas-mediated or not is
unknown.
In a recent study in measles virus by Hahm et al. (2005) show
that measles virus downregulate MHC class II expression in DCs
which may be responsible for immunosuppression caused by
measles virus. In our study we also found that NiV infection of
DCs downregulate MHC class II levels. Whereas there is a
signiﬁcant increase in the levels of co-stimulatory molecules
compared to controls on DCs. NiV infected DCs do not activate T
cell efﬁciently. On the other note inactivated NiV and inactivated
Ebola virus treated DCs able to unregulate MHC class II levels and
also activate T cells. This suggests that NiV may induce insufﬁcient
activation of DCs that might be responsible for T cellsunresponsiveness. Mechanism by which NiV downregulate MHC
class II levels has to be determined. We also observed two distinct
populations of DCs one that unregulates CD80 levels and one that
does not have high levels of CD80. The reason of this distinct
population is possibly due to insufﬁcient signaling of Nipah
antigen and causing for T cell unresponsiveness.
DCs co-cultured with T cells do not efﬁciently activate CD4 and
CD8 T cells populations. Both CD4 and CD8 T cells also fail to
proliferate in live NiV infected DC cultures (data not shown).
In fact, T cells show downregulation of bcl2 and upregulated active
caspase 3, suggestive of apoptosis. T cells infected with measles
virus undergo anergy and/or death when co-cultured with DCs
(Kerdiles et al., 2006; Okada et al., 2000). T cell apoptosis and/or
anergy require MHC complex-T cell receptor interaction induced
by DCs (Grosjean et al., 1997). T cells also express receptors for NiV,
and NiV may infect T cells (Mathieu et al., 2011). To test whether T
cell apoptosis is mediated directly by NiV or through DCs, we
infected T cells with live or inactivated NiV without DCs. We found
no activation or cell death (indicated by bcl2 and active caspase 3)
in the absence of DCs, suggesting that T cell apoptosis requires
MHC-T cell interaction.
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apoptosis in DCs and T cells in DC/T cells co-cultures. This suggests
that cell death in DCs is not replication-dependent. It has been
previously shown that measles virus attachment glycoprotein can
cause apoptosis in PBMCs (Iwasa et al., 2010). We do not know yet
if NiV glycoprotein can also cause apoptosis in DCs. DCs treated
with inactivated NiV can activate CD4 T and CD8 cells better than
those given live virus and show less cell death. NiV proteins,
factors, and mechanism causing DC death remain to be identiﬁed.
Under the limitations of in vitro study, this is the ﬁrst study
showing that NiV infection alters DC function. NiV infection of DCs
does not induce anti-viral cytokines, such as IFN-α and IFN-β, but
induces inﬂammatory cytokines like TNF-α, IP-10. Also induces
cytokines IL-8, IL-10 an indication that it can suppress the host
immune response by multiple pathways. NiV infection transiently
activates DCs early on and subsequently induces their cell death.
However, the transiently activated DCs are unable to activate T
cells sufﬁciently to mount an anti-viral immune response. Our
study provides new insights into NiV immune modulation and will
possibly help to understand the mechanisms of NiV pathogenesis.Materials and methods
Virus
NiV (strain 810573, accession AF212302 isolated from a patient
of the 1998–1999 Malaysia outbreak) was grown in Vero-E6 cells.
All experiments with live virus were done in a BSL-4 laboratory at
Centers for Disease Control and Prevention (Atlanta, GA, USA).
Puriﬁcation of NiV
Vero-E6 cells grown in a monolayer were infected with
5107 pfu/mL of NiV. On day 5, the supernatant was collected,
centrifuged at 2000 rpm for 10 min to remove cell debris, and
stored at −70 1C. For puriﬁcation, 12 mL of 25% glycerol in TNE
(Tris–NaCl-EDTA) solution was added ﬁrst, and 22 mL of the
supernatant was carefully layered on top, and centrifuged at
25,000 rpm speed for 4 h in an SW28 rotor (Beckman Coulter,
Brea, CA, USA). After centrifugation, the supernatant was decanted
and the pellet was re-suspended in phosphate buffered saline
(PBS) overnight at 4 1C. Viral titer was measured by plaque assay.
Isolation and puriﬁcation of monocyte-derived DCs and T cells from
peripheral blood mononuclear cells (PBMCs)
Aphaeresis from healthy donors was collected randomly and
layered on a ﬁcoll gradient medium (ICN Biomedicals, Aurora, OH,
USA). Approximately 10 different donors were used to collect
blood. Isolated PBMCs were washed, and monocytes were sepa-
rated using magnetic beads (Miltenyi Biotec, Auburn, CA, USA)
following the manufacturer's protocol. Monocytes were plated on
6-well plates at the concentration of 2106 cells/well, and
allowed to adhere for 40 min. Non-adhering cells were removed
and adherent cells were re-suspended in RPMI media containing
10% Fetal Calf Serum (FCS), 50 ng/mL interleukin 4 (IL-4), and
GM-CSF (granulocyte-monocyte colony stimulating factor). Media
was supplemented with 50 ng/mL of IL-4 and GM-CSF on days 0, 3,
and 5, as shown before (Raftery et al., 2002). On day 7, the cells
were harvested and tested for DC purity by CD1a-APC and Class II
staining. Over 99% of the cells were positive for CD1a and Class II. T
cells were isolated using magnetic beads as described above. T cell
identity and purity were determined by CD3 staining. Over 99%
cells were positive for CD3.Infection protocol
DCs were infected with 5 multiplicity of infection (MOI) of
either puriﬁed live or inactivated NiV. Virus was inactivated by
gamma radiated using 5106 rads. Inactivation was tested by the
absence of virus growth after a double blind passage in Vero E6
cells. DCs were also infected with puriﬁed inactivated Ebola virus
(1 MOI) grown in Vero-E6 cells as a positive control for DC
activation. After infection, DCs were mixed with T cells in 1:3
ratio, and activation and apoptosis were determined. T cells were
incubated with DC infected live or killed Nipah virus until they
were tested for activation and apoptosis signals for example day
5 or day 8 post infection. In some experiments, puriﬁed T cells
were directly infected with 5 MOI of puriﬁed NiV or treated with
puriﬁed inactivated NiV. Cells were examined by ﬂow cytometry
for activation and apoptosis markers on day 8 post-infection.Real-time PCR for determining NiV genome copy number
To determine NiV genome copy numbers, we used the NIP3END
primer 5′-ACCAAACAAGGGAGAATATGGATAC-3′ to reverse tran-
scribe total RNA (8 μL) extracted from DCs infected with puriﬁed
NiV. We used the Superscript III First Strand Synthesis kit (Invitro-
gen, Grand Island, NY, USA) according to manufacturer's protocols.
The resulting cDNA was diluted 1:5, and 2.0 μL of cDNA per sample
was used in a 25 μL (total volume) RT2 SYBR green/ROX real-time
PCR reaction using primers adapted from a real-time Taqman RT-
PCR previously described (Lo et al., 2012). Synthetic NiV N RNA
standards of known quantity (∼109 copies/μL) were reverse-
transcribed using primer NIPN9 5′-TCACACATCAGCTCTGACGAA-3′
in a 20 μL reaction, and diluted 1:5; 2.0 μL of these cDNA samples
were used to make 10-fold dilutions to generate a standard curve
for NiV N gene copy number. We normalized the NiV N gene copy
numbers to total ng of RNA based on a standard curve plotting ng of
RNA versus Ct levels of GAPDH using primers previously described
(Lo et al., 2010).Surface and intracellular staining
To identify surface markers, cells were incubated on ice with
50 μL of mouse anti-human CD1a-APC, Fas-PE, Class I-PE, Class
II-PE, CD40-PE, CD80-PE, CD86-PE, or isotype controls for 30 min.
All antibodies were purchased from BD Pharmingen (San Diego,
CA, USA). After incubation, cells were washed and permeabilized
using a cytoﬁx kit (BD Pharmingen) according to the manufac-
turer's instructions. After permeabilization, cells were incubated
with active caspase 3-PE, Bcl2-PE, and isotype controls for 30 min
on ice. Unadsorbed labeled antibodies were washed away by using
centrifugation, and cells were ﬁxed with 0.4% paraformaldehyde
and stored at 4 1C until processing. Approximately 40,000 cells
were counted in each sample. Cells were gated on CD1a markers
above Mean Florescent Intensity (MFI) values of the isotype
controls (MFI of 20).
T cells were tested for activation markers on CD4 and CD8 T
cells using CD25-PE, CD62L-PE, CD44-PE, or isotype control (BD
Pharmingen) as described above. For intracellular staining, cells
were permeabilized with cytoﬁx/cytoperm buffer and stained for
Bcl2 and active caspase 3. Cells were ﬁxed with 0.2% paraformal-
dehyde and read on FACSCalibur.
We also tested ephrin B2 and B3 levels in monocyte-derived DCs.
Vero-E6 cells were used as positive control. Fc receptors were
blocked on DCs with rabbit IgG (10 μg/mL). Primary antibodies
against ephrin B2 and B3, and isotype controls, were purchased
from Abcam Biotech (Cambridge, MA, USA).
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signals were acquired on FACS Calibur inside the BSL-4 laboratory,
and analyzed with FACS FlowJo (BD Pharmingen) software.
Immunoﬂuorescent assays (IFA)
5104 monocyte-derived DCs were plated on glass coverslip in
24-well plates. Cells were infected with 5 MOI of puriﬁed NiV or
treated with puriﬁed inactivated NiV for 1 h. After 24 h, cells were
ﬁxed in 4% paraformaldehyde for 10 min. All infections were done
in the BSL-4 laboratory. Plates were treated with 5106 rads of
gamma radiation and developed in BSL-2 laboratory. Cells were
permeabilized with 0.1% Triton-X for 5 min and washed with PBS.
Cells were stained with 1:500 dilution of polyclonal antibody
against NiV antigens, and anti-mouse FITC antibody made in goats
as the secondary antibody (1:1000 dilution). All antibodies were
applied for 30 min at room temperature. Cells were washed
3 times with PBS between antibody applications. Cells were
mounted in glycerol containing DAPI.
Cytokine detection using Luminex beads
Levels of 26 cytokines and chemokines were detected using
Luminex technology (Luminex Corp., Austin, TX, USA). One custo-
mized cytokine kit was used according to manufacturer's instruc-
tions. The target cytokines were interleukins (IL) IL-1α, IL-1β, IL-10,
IL-6, IL-12p40, IL-12p70, monocyte chemotactic protein 1 (MCP-1),
macrophage inﬂammatory protein (MIP)-1α, MIP-1β, tumor necro-
sis factor (TNF)-α, TNF-β, interferon α2 (IFN-α2), IFN-γ, IFN-
inducible protein (IP-10), T-cell growth factor α (TGF-α), regu-
lated-on-activation, normal T-cell expressed, and secreted
(RANTES), and vascular cell adhesion molecule-1 (VCAM-1).
Samples were collected from DCs infected with 5 MOI of live or
inactivated NiV. Culture supernatants were collected on days 1, 2,
3, and 4 post-infection. All infections were performed in a BSL-4
laboratory. Cell supernatants were inactivated with 5106 rads of
gamma radiation and processed under BSL-2 conditions; previous
studies show that the irradiation process does not affect the
cytokine assay (Mahanty et al., 1999). Brieﬂy, 25 μL of cell culture
supernatants were incubated with antibody-coupled beads for 1 h
at room temperature. The beads were then incubated at room
temperature with detector antibody for 1 h, and with streptavi-
din–phycoerythrin for 30 min. Finally, the complexes were washed
and re-suspended in running buffer. The beads were washed
3 times between each step according to manufacturer's instruc-
tions. 100 beads per cytokine were acquired using Luminex 400.
Mean ﬂuorescent intensity was measured to calculate ﬁnal cyto-
kine concentrations in pg/mL.Disclaimer
The views expressed in this article are solely those of the authors
and do not repesent the ofﬁcial views or opinions of the Institute.
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